Increasing Prevalence of HIV-1 Reverse Transcriptase Mutation K65R Correlates with Tenofovir Utilization

Srinivas R.V. , & Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrobial Agents & Chemotherapy 1998, 42: 1484–1487.

Wainberg M.A. , Miller M.D. , Quan Y. , Salomon H. , Mulato A.S. , Lamy P.D. , Margot N.A. , Anton K.E. , & Cherrington J.M. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999, 4: 87–94.

Garcia-Lerma J.G. , Gerrish P.J. , Wright A.C. , Qari S.H. , & Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. Journal of Virology 2000, 74: 9339–9346.

Farthing C. , Khanou H. , & Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. 13–16 July 2003, Paris, France. Abstract 43.

Gallant J.E. , Rodriguez A.E. , Weinberg W. , Young B. , Berger D. , Lim M.L. , Liao Q. , Ross L. , Johnson J. , & Shaefer M.S. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14–17 September 2003, Chicago, Ill., USA. Abstract H-1722a.